Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sierra Oncology, Inc. - Common Stock (NQ:SRRA)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 30, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Sierra Oncology, Inc. - Common Stock

< Previous 1 2 Next >
Sierra Oncology Announces Submission of New Drug Application for Momelotinib to US Food & Drug Administration
From Sierra Oncology
Via Business Wire
Momelotinib Pivotal Phase 3 Data Receives Oral Presentation at American Society of Clinical Oncology Annual Meeting
From Sierra Oncology
Via Business Wire
Sierra Oncology Announces Oral Presentation of Momelotinib Pivotal Phase 3 Data at European Hematology Association Annual Meeting
From Sierra Oncology
Via Business Wire
Sierra Oncology Reports First Quarter 2022 Results
From Sierra Oncology
Via Business Wire
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Sierra Oncology
Via Business Wire
SIERRA ONCOLOGY INVESTOR ALERT - Kuznicki Law PLLC Investigates Proposed Sale of Sierra Oncology, Inc - SRRA
From Kuznicki Law PLLC
Via Business Wire
SIERRA ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sierra Oncology, Inc - SRRA
From Kahn Swick & Foti, LLC
Via Business Wire
Advancements of CAR-T Cell Therapies Importance Grows While Cancer Cases Increasing
Palm Beach, FL – April 14, 2022 – FinancialNewsMedia.com News Commentary – CAR-T therapy is a sort of treatment in which a patient’s T cells which is a type of immune system cell, are genetically... 
Via FinancialNewsMedia
SRRA Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Sierra Oncology, Inc. Is Fair to Shareholders
From Halper Sadeh LLP
Via Business Wire
GSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company Sierra Oncology For $1.9bn
From Sierra Oncology
Via Business Wire
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Sierra Oncology
Via Business Wire
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Sierra Oncology
Via Business Wire
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Sierra Oncology
Via Business Wire
Sierra Oncology Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Sierra Oncology
Via Business Wire
Sierra Oncology to Participate in Guggenheim Oncology Conference
From Sierra Oncology
Via Business Wire
Sierra Oncology Announces Closing of Upsized Public Offering of $135.0 Million of Securities
From Sierra Oncology
Via Business Wire
R&D Spending Increases Exponentially for Higher Standard of Breast Cancer Drug Treatments
Palm Beach, FL – January 27, 2022 – FinancialNewsMedia.com News Commentary – According to International Agency for Research on Cancer (IARC) published by the World Health Organization (WHO) in 2018,... 
Via FinancialNewsMedia
Topics Death Intellectual Property
Exposures Death Intellectual Property
Sierra Oncology to Present at B. Riley Securities Oncology Investor Conference
From Sierra Oncology
Via Business Wire
Sierra Oncology Announces Pricing of Upsized Public Offering of Securities
From Sierra Oncology
Via Business Wire
Sierra Oncology Announces Proposed Public Offering of Common Stock
From Sierra Oncology
Via Business Wire
Sierra Oncology Provides Financial Update to Support the Future Commercialization of Momelotinib
From Sierra Oncology
Via Business Wire
Sierra Oncology Announces Momelotinib Achieved Statistically Significant Benefit on Symptoms, Anemia and Splenic Size in the Pivotal MOMENTUM Study for Myelofibrosis
From Sierra Oncology
Via Business Wire
Momelotinib Review Article Published in Journal of Hematology & Oncology Highlights Importance of Anemia Benefit for Myelofibrosis Patients
From Sierra Oncology
Via Business Wire
Sierra Oncology Updates Topline Data Timing for Pivotal Phase 3 Trial of Momelotinib in Myelofibrosis
From Sierra Oncology
Via Business Wire
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Sierra Oncology
Via Business Wire
Sierra Oncology to Present at HC Wainwright BioConnect Conference
From Sierra Oncology, Inc.
Via Business Wire
Sierra Oncology Reports Baseline Ferritin Differentially Predicts Week 24 Transfusion Independence Response in Myelofibrosis Patients
From Sierra Oncology
Via Business Wire
Sierra Oncology Announces Investor Event to Review MOMENTUM Trial Design and Available Phase 3 Momelotinib Data in Myelofibrosis
From Sierra Oncology
Via Business Wire
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Sierra Oncology
Via Business Wire
Sierra Oncology Announces Presentation at Jefferies London Healthcare Conference
From Sierra Oncology
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.